TIMI Study Group

TIMI is proud to celebrate our 40th anniversary! Since 1984, we've been dedicated to advancing the knowledge and care of patients suffering from cardiovascular disease and its risk factors. View the 40th anniversary edition of the TIMI book, now online.
timi.org/40th-anniversa…

Among patients with diabetes or atherosclerosis, but without a prior MI or stroke, those with CKD are at high risk for CV outcomes and death. Intensive LDL-C lowering to ~45mg/dL with #evolocumab substantially attenuates this risk. See details online at @JACC. @ebohula #AHA26

Endothelial cell polygenic risk score association with CCTA-defined extensive coronary plaque is modified by LDL-C, suggesting a role for endothelial genetic susceptibility in LDL-related atherogenesis #AHA26

Among patients without overt #ASCVD, leukocyte telomere length polygenic score independently predicts CV events beyond clinical risk factors and CAD polygenic risk. #AHA26

If proven to be effective for stroke prevention in AF, FXI inhibition with #abelacimab may be particularly advantageous in high-risk patients with AF and history of bleeding #AHA26